US · Healthcare · Medical Devices
EPS came in at 1.07 against a street estimate of 1.21 — a miss of 11.6%.
Analysts rate Penumbra Inc a hold (3 buy, 14 hold, 0 sell out of 17) with an average price target of $362.54.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.91% |
| HBK INVESTMENTS L P | 4.67% |
| Vanguard Capital Management, LLC | 4.34% |
| Vanguard Portfolio Management, LLC | 4.23% |
| State Street Corp | 3.16% |
| ExodusPoint Capital Management, LP | 2.77% |
| Balyasny Asset Management LLC | 2.77% |
| JPMorgan Chase & Co | 2.72% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $410,145 thousand, up from $354,685 thousand in the third quarter of 2025. • Nine-month 2026 reven | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $410.1 million, up 15.6% from Q3 2025. Nine-month revenue was $1,174.9 million, up 15.4%. • Q3 income from op | 2026-10-29 |
| Quarterly report · Q2 2026 PENUMBRA, INC. - FORM 10-Q SUMMARY For Quarterly Period Ended June 30, 2026 --- HEADLINE NUMBERS • Revenue Q2 2026: $390.0 million (vs. $339.5 mill | 2026-07-30 |
| Results announced · Q3 2026 PENUMBRA, INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue: $390.0 million in Q2 2026, up 14.9% year-over-year from $339.5 million | 2026-07-30 |
| Shareholder vote results · Q2 2026 PENUMBRA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 18, 2026 • 39,331,425 shares outstanding as of record date (April 22, | 2026-06-22 |
| Shareholder vote results · Q2 2026 PENUMBRA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merger approval vote date: May 6, 2026 • Shares outstanding (record date March 26, 2026): 39,32 | 2026-05-07 |
| Quarterly report · Q1 2026 PENUMBRA, INC. - FORM 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Revenue Q1 2026: $374.8 million (up 15.6% vs. Q1 2025: $324.1 million) • Net income | 2026-05-06 |
| Results announced · Q2 2026 PENUMBRA, INC. Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue: $374.8 million in Q1 2026, up 15.6% vs. Q1 2025 ($324.1 million) • Gross | 2026-05-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Merger agreement with Boston Scientific Corporation announced Boston Scientific Corporation is acquiring Penumbra, Inc. for approximately $374 per share in cash (73.26% of shares) or 3.8721 Boston Scientific shares per Penumbra share (26.74% of shares) | 2026-01-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Penumbra Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.